Literature DB >> 11898555

Of replications and refutations: the status of Alzheimer's disease genetic research.

L Bertram1, R E Tanzi.   

Abstract

Alzheimer's disease (AD) is a genetically complex and heterogeneous disorder. To date, mutations in three genes (APP, PSEN1, PSEN2) have been described to cause familial early-onset AD. In addition, a common polymorphism in the gene encoding apolipoprotein E (APOE) has been associated with the more common late-onset form of the disease. However, many studies have shown that genetic factors other than APOE play an important role in late-onset AD. Along these lines, a recent report predicted the existence of at least four additional late-onset AD genes, one of which was estimated to have a much greater contribution to age of onset variation than the APOE epsilon 4-allele. However, most of the nearly three dozen loci that have been proposed as putative AD genes to date have been followed by both replications and refutations, making consensus impossible. In this overview, we discuss the current status of genetic research in AD, including a brief summary of applicable analytic tools, and a summary of recent findings suggesting the existence of novel AD genes on chromosomes 10, 11, and 12.

Entities:  

Mesh:

Year:  2001        PMID: 11898555     DOI: 10.1007/s11910-001-0104-9

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  58 in total

1.  No association between an intronic biallelic polymorphism of the FE65 gene and Alzheimer's disease.

Authors:  A Papassotiropoulos; M Bagli; K Becker; F Jessen; W Maier; M L Rao; M Ludwig; R Heun
Journal:  Int J Mol Med       Date:  2000-11       Impact factor: 4.101

2.  Linkage studies in familial Alzheimer disease: evidence for chromosome 19 linkage.

Authors:  M A Pericak-Vance; J L Bebout; P C Gaskell; L H Yamaoka; W Y Hung; M J Alberts; A P Walker; R J Bartlett; C A Haynes; K A Welsh
Journal:  Am J Hum Genet       Date:  1991-06       Impact factor: 11.025

3.  Alpha2-macroglobulin polymorphisms in Italian sporadic and familial Alzheimer's disease.

Authors:  B Nacmias; A Tedde; E Cellini; P Forleo; A Orlacchio; B M Guarnieri; C Petruzzi; F D'Andrea; A Serio; S Sorbi
Journal:  Neurosci Lett       Date:  2001-02-16       Impact factor: 3.046

4.  The genetic association between Cathepsin D and Alzheimer's disease.

Authors:  F C Crawford; M J Freeman; J Schinka; L I Abdullah; D Richards; S Sevush; R Duara; M J Mullan
Journal:  Neurosci Lett       Date:  2000-07-28       Impact factor: 3.046

5.  Association between an alpha(2) macroglobulin DNA polymorphism and late-onset Alzheimer's disease.

Authors:  V Alvarez; R Alvarez; C H Lahoz; C Martínez; J Peña; L M Guisasola; J Salas-Puig; G Morís; D Uría; B B Menes; R Ribacoba; J A Vidal; J M Sánchez; E Coto
Journal:  Biochem Biophys Res Commun       Date:  1999-10-14       Impact factor: 3.575

6.  SNPing away at complex diseases: analysis of single-nucleotide polymorphisms around APOE in Alzheimer disease.

Authors:  E R Martin; E H Lai; J R Gilbert; A R Rogala; A J Afshari; J Riley; K L Finch; J F Stevens; K J Livak; B D Slotterbeck; S H Slifer; L L Warren; P M Conneally; D E Schmechel; I Purvis; M A Pericak-Vance; A D Roses; J M Vance
Journal:  Am J Hum Genet       Date:  2000-06-21       Impact factor: 11.025

7.  A polymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia.

Authors:  M J Bullido; M J Artiga; M Recuero; I Sastre; M A García; J Aldudo; C Lendon; S W Han; J C Morris; A Frank; J Vázquez; A Goate; F Valdivieso
Journal:  Nat Genet       Date:  1998-01       Impact factor: 38.330

8.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.

Authors:  W J Strittmatter; A M Saunders; D Schmechel; M Pericak-Vance; J Enghild; G S Salvesen; A D Roses
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

9.  Genetic association of an alpha2-macroglobulin (Val1000lle) polymorphism and Alzheimer's disease.

Authors:  A Liao; R M Nitsch; S M Greenberg; U Finckh; D Blacker; M Albert; G W Rebeck; T Gomez-Isla; A Clatworthy; G Binetti; C Hock; T Mueller-Thomsen; U Mann; K Zuchowski; U Beisiegel; H Staehelin; J H Growdon; R E Tanzi; B T Hyman
Journal:  Hum Mol Genet       Date:  1998-11       Impact factor: 6.150

10.  Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium.

Authors:  L A Farrer; L A Cupples; J L Haines; B Hyman; W A Kukull; R Mayeux; R H Myers; M A Pericak-Vance; N Risch; C M van Duijn
Journal:  JAMA       Date:  1997 Oct 22-29       Impact factor: 56.272

View more
  5 in total

1.  Clinic visits and prescribing patterns among Veterans Affairs Maryland Health Care System dementia patients.

Authors:  G B Rattinger; C D Mullins; I H Zuckerman; E Onukwugha; S Delisle
Journal:  J Nutr Health Aging       Date:  2010-10       Impact factor: 4.075

2.  Lens defects and age-related fiber cell degeneration in a mouse model of increased AbetaPP gene dosage in Down syndrome.

Authors:  Peter H Frederikse; Xiao-Ou Ren
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

Review 3.  Alzheimer's genetics in the GWAS era: a continuing story of 'replications and refutations'.

Authors:  Lars Bertram
Journal:  Curr Neurol Neurosci Rep       Date:  2011-06       Impact factor: 5.081

Review 4.  Dancing in the dark? The status of late-onset Alzheimer's disease genetics.

Authors:  L Bertram; R E Tanzi
Journal:  J Mol Neurosci       Date:  2001-10       Impact factor: 3.444

5.  Upregulation of CRABP1 in human neuroblastoma cells overproducing the Alzheimer-typical Abeta42 reduces their differentiation potential.

Authors:  Markus Uhrig; Peter Brechlin; Olaf Jahn; Yuri Knyazev; Annette Weninger; Laura Busia; Kamran Honarnejad; Markus Otto; Tobias Hartmann
Journal:  BMC Med       Date:  2008-12-16       Impact factor: 8.775

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.